2021
| Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities. A Randomized Clinical Trial | 14.06.2021 (Silvio Ragozzino) Cohen MS et al.: Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities. A Randomized Clinical Trial JAMA June 3, 2021. Online ahead of print. |
| Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis | 07.06.2021 (Anne-Valérie Burgener) S.E. Dorman: Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis NEJM 384 1705-1718 2021 |
| Pujol M. et al.: Daptomycin plus Fosfomycin versus Daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial | 31.05.2021 (Andreas Neumayr) Pujol M. et al.: Daptomycin plus Fosfomycin versus Daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial Clin Infect Dis 72 1517–25 2021 |
| Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/ VESTED) | 17.05.2021 (Mihaela Sava) Lockman S, Brummel S et al.: Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/ VESTED) The Lancet 397 1276-92 2021 |
| Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. | 10.05.2021 (Capoferri Gioele) François B. et al.: Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. SAATELLITE Studie Online Online 2021 |
| Discontinuing Beta-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial | 03.05.2021 (Elisabeth Wehrle) Dinh A. et al.: Discontinuing Beta-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial The Lancet 397 1195-1203 2021 |
| Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination | 26.04.2021 (Simon Egli) R. R. Goel et al.: Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination Sci. Immunol. Vol. 6, Issue 58 noch nicht definitiv 2021 |
| Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study | 12.04.2021 (Pascal Urwyler) Hansen C. H. et al.: Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study Lancet 397 1204–12 2021 |
| Attributes and predictors of long COVID | 29.03.2021 (Aurélien Martinez) Sudre C et al.: Attributes and predictors of long COVID Nature medicine 2021 |
| Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study | 22.03.2021 (von Rotz Matthias) Challen R. et al.: Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study BMJ 372:n579 1-10 2021 |
| Comparable outcomes of short-course and prolonged-course therapy in selected cases of methicillin-susceptible Staphylococcus aureus bacteremia: A pooled cohort study | 15.03.2021 (Richard Kühl) Louise Thorlacius-Ussing et al.: Comparable outcomes of short-course and prolonged-course therapy in selected cases of methicillin-susceptible Staphylococcus aureus bacteremia: A pooled cohort study CID Online ahead of print: 2021 Mar 2;ciab201. doi: 10.1093/cid/ciab201. 2021 |
| 1) Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 2) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial | 08.03.2021 (Silvio Ragozzino) 1) Gordon A.C. et al. 2) Horby P.W. et al.: 1) Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 2) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial 1) NEJM, February 25, 2021 2) MedRxiv (preprint), February 11, 2021 |
| Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study | 01.03.2021 (Andreas Neumayr) Neumayr A. et al.: Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study |
| 1) Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England:4 June to November 2020 2) Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey 3) The contribution of nosocomial infections to the first wave | 22.02.2021 (Ana Durovic) 1) Hall V et al 2) Koen B Pouwels, Thomas House et al: 1) Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England:4 June to November 2020 2) Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey 3) The contribution of nosocomial infections to the first wave 1) medRxiv preprint: https://doi.org/10.1101/2021.01.13.21249642 2) Lancet Public Health https://doi.org/10.1016/S2468-2667(20)30282-6 3) 63.+78. SAGE meeting on COVID-19 2021 |
| Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: phase 3, randomised, controlled, non-inferiority trial | 15.02.2021 (Mihaela Sava) Maertens JA et al.: Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: phase 3, randomised, controlled, non-inferiority trial The Lancet 397 499-509 2021 |
| Interim Resukts of a Pahse 1-2a trial of Ad26.COV2.S Covid-19 Vaccine | 08.02.2021 (Anne-Valérie Burgener) J. Sadoff et al.: Interim Resukts of a Pahse 1-2a trial of Ad26.COV2.S Covid-19 Vaccine NEJM Januray 13, 2021. DOI:10.1056/NEJMoa2034201 2021 |
| Evaluation of Partial Oral Antibiotic Treatment for Persons Who Inject Drugs and Are Hospitalized With Invasive Infections | 01.02.2021 (Pascal Urwyler) Marks L.R. et al.: Evaluation of Partial Oral Antibiotic Treatment for Persons Who Inject Drugs and Are Hospitalized With Invasive Infections Clinical Infectious Diseases 71(10) 650–6 2020 |
| Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance | 25.01.2021 (Sabine Kuster) Koehler P et al.: Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance Lancet Infect Dis Published online, December 14 1-14 2020 |
| Treatment of Highly Drug-Resistant Pulmonary Tuberculosis | 18.01.2021 (Aurélien Martinez) Francesca Conradie et al.: Treatment of Highly Drug-Resistant Pulmonary Tuberculosis The New England Journal of Medicine 382 893-302 2021 |
| Antibody Status and Inicidence of SARS-CoV-2 Infection in Health Care Workers | 11.01.2021 (Sandra Zingg) Lumley S.F. et al: Antibody Status and Inicidence of SARS-CoV-2 Infection in Health Care Workers NEJM Decemeber 23, 2020 |